2. Apoptosis GPCR/G Protein MAPK/ERK Pathway Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. Ferroptosis Prostaglandin Receptor MDM-2/p53 JNK Reactive Oxygen Species
  4. Seratrodast

Seratrodast  (Synonyms: AA 2414)

Cat. No.: HY-B0774 Purity: 98.86%
SDS COA Handling Instructions

Molarity Calculator

Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity.

For research use only. We do not sell to patients.

Seratrodast Chemical Structure

Seratrodast Chemical Structure

CAS No. : 112665-43-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 47 In-stock
Solution
10 mM * 1 mL in DMSO USD 47 In-stock
Solid
5 mg USD 25 In-stock
10 mg USD 43 In-stock
25 mg USD 76 In-stock
50 mg USD 107 In-stock
100 mg USD 150 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Seratrodast:

Seratrodast Related Antibodies

Top Publications Citing Use of Products

View All Prostaglandin Receptor Isoform Specific Products:

View All Isoforms
DP EP FP IP TXA2/TP TXB2

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity[1][2][3].

IC50 & Target

TXA2/TP

 

JNK

 

In Vitro

Pretreatment with Seratrodast (5 μM; 2 h) can inhibit ferroptosis induced by RSL3 (HY-100218A) or Erastin (HY-15763) in HT22 cells; and down-regulate the phosphorylation level of JNK[3]/ Pretreatment with s
Seratrodast (5, 10 μM; 2 h) can inhibit ROS generation and lipid peroxidation induced by 1 μM Erastin (HY-15763) in HT22 cell[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Seratrodast Related Antibodies

Cell Viability Assay[3]

Cell Line: HT22 cells
Concentration: 2.5, 5, 10, or 20 μM
Incubation Time: 24 h
Result: Did not show significant cytotoxicity at Seratrodast concentrations below 10 μM after 2 or 24 h.
Prevented cell death in HT22 cells induced by ferroptosis inducer.
In Vivo

Seratrodast (3, 9, 20 mg/kg; po; pre-treated, once daily for 5 days) inhibits neuronal ferroptosis in the pentylenetetrazole-induced mouse epilepsy model, thereby reducing epileptic seizure[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

354.44

Formula

C22H26O4
CAS No.
Appearance

Solid

Color

Yellow to orange

SMILES

CC(C1=O)=C(C(C(C)=C1C)=O)C(C2=CC=CC=C2)CCCCCC(O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (282.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8214 mL 14.1068 mL 28.2135 mL
5 mM 0.5643 mL 2.8214 mL 5.6427 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.86%

SDS (392 KB)

COA (248 KB) HNMR (269 KB) LCMS (94 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8214 mL 14.1068 mL 28.2135 mL 70.5338 mL
5 mM 0.5643 mL 2.8214 mL 5.6427 mL 14.1068 mL
10 mM 0.2821 mL 1.4107 mL 2.8214 mL 7.0534 mL
15 mM 0.1881 mL 0.9405 mL 1.8809 mL 4.7023 mL
20 mM 0.1411 mL 0.7053 mL 1.4107 mL 3.5267 mL
25 mM 0.1129 mL 0.5643 mL 1.1285 mL 2.8214 mL
30 mM 0.0940 mL 0.4702 mL 0.9405 mL 2.3511 mL
40 mM 0.0705 mL 0.3527 mL 0.7053 mL 1.7633 mL
50 mM 0.0564 mL 0.2821 mL 0.5643 mL 1.4107 mL
60 mM 0.0470 mL 0.2351 mL 0.4702 mL 1.1756 mL
80 mM 0.0353 mL 0.1763 mL 0.3527 mL 0.8817 mL
100 mM 0.0282 mL 0.1411 mL 0.2821 mL 0.7053 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Seratrodast Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Seratrodast112665-43-7AA 2414AA2414AA-2414FerroptosisProstaglandin ReceptorMDM-2/p53JNKReactive Oxygen Speciesc-Jun N-terminal kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Seratrodast
Cat. No.:
HY-B0774
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.